Traditional Chinese medicine-facilitated redox-labile paclitaxel dimer nanoprodrug for efficient chemoimmunotherapy
Journal of Pharmaceutical Analysis · 2025-09 · 15 (9) · 101348
DOI: 10.1016/j.jpha.2025.101348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2025-09. Verfasst von Fan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, 230031, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Various therapeuti modailities have been engineered for lung cancer treatment, but their clinic application is severely impeded by the poor therapy efficiency and immunosuppressive microenvironment. Herein, we fabricated a library of small molecule redox-labile nanoparticles (NPs) (i.e., diPTX-2C NPs, diPTX-2S NPs, and diPTX-2Se NPs) by the self-assembly of dimer paclitaxel (PTX) prodrug, and then utilized these NPs with the traditional Chinese medicine (TCM) Qi-Yu-San-Long-Fang (Q) for effective chemoimmunotherapy on Lewis lung carcinoma (LLC)-bearing mice models. Under the high concentration of glutathione (GSH) and H2O2, diPTX-2Se NPs could specifically release PTX in cancer cells and exert a higher selectivity and toxicity than normal cells. In LLC tumor-bearing mice, oral administration of Q not only effectively downregulated programmed death ligand-1 (PD-L1) expression, but also remodeled the immunosuppressive tumor immune microenvironment via the increase of CD4+ T and CD8+ T cell proportion and the repolarization of M2 into M1 macrophages in tumor tissues, collectively achieving superior synergistic treatment outcomes in combination with intravenous PTX prodrug NPs. Besides, we found that the combination regimen also demonstrated excellent chemoimmunotherapeutic performances on low-dose small established tumor and high-dose large established tumor models. This study may shed light on the potent utilization of Chinese and Western-integrative strategy for efficient tumor chemoimmunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, 230031, China.
- Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, 233004, China.
- The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China.
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China.
- School of Traditional Chinese Medicine, Anhui University of Chinese Medicine, Hefei, 230012, China.
Zitieren
APA
Li, F., Wang, W., Xu, W., Li, W., Lu, Y., Wang, R., He, Z., Feng, Z., Tong, J., & Li, Z. (2025). Traditional Chinese medicine-facilitated redox-labile paclitaxel dimer nanoprodrug for efficient chemoimmunotherapy. Journal of Pharmaceutical Analysis, 15(9), 101348. https://doi.org/10.1016/j.jpha.2025.101348
Vancouver
Li F, Wang W, Xu W, Li W, Lu Y, Wang R, et al. Traditional Chinese medicine-facilitated redox-labile paclitaxel dimer nanoprodrug for efficient chemoimmunotherapy. Journal of Pharmaceutical Analysis. 2025;15(9):101348. doi:10.1016/j.jpha.2025.101348
BibTeX
@article{Li2025,
author = {Li, Fan and Wang, Wenrui and Xu, Weisheng and Li, WanYing and Lu, Yudi and Wang, Rui and He, Zhonggui and Feng, Zhihui and Tong, Jiabing and Li, Zhenbao},
title = {Traditional Chinese medicine-facilitated redox-labile paclitaxel dimer nanoprodrug for efficient chemoimmunotherapy},
journal = {Journal of Pharmaceutical Analysis},
year = {2025},
volume = {15},
number = {9},
pages = {101348},
doi = {10.1016/j.jpha.2025.101348}
}
EUVIMED